Gerber Hans-Peter 4

4 · SUTRO BIOPHARMA, INC. · Filed Mar 3, 2026

Form 4

Period: 2026-03-01

CHIEF SCIENTIFIC OFFICER

Transactions

Exercise/Conversion
Common Stock
2026-03-01+1,125→ 8,308 total
Tax Payment
Common Stock
[F1]
2026-03-01$20.47/sh−463$9,478→ 7,845 total
Exercise/Conversion
Common Stock
2026-03-02+2,843→ 10,688 total
Tax Payment
Common Stock
[F1]
2026-03-02$20.55/sh−1,170$24,044→ 9,518 total
Exercise/Conversion
Restricted Stock Units (RSUs)
[F2][F3]
2026-03-01−1,125→ 2,250 total
Exp: 2028-03-01→ Common Stock (1,125 underlying)
Exercise/Conversion
Restricted Stock Units (RSUs)
[F2][F4]
2026-03-02−2,843→ 8,532 total
Exp: 2029-03-02→ Common Stock (2,843 underlying)
Award
Restricted Stock Units (RSUs)
[F2][F5]
2026-03-02+5,000→ 5,000 total
Exp: 2030-03-01→ Common Stock (5,000 underlying)
Award
Stock Option (right to buy)
[F6]
2026-03-02+40,000→ 40,000 total
Exercise: $20.55Exp: 2036-03-02→ Common Stock (40,000 underlying)

Footnotes (6)

[F1]Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
[F2]Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
[F3]The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on March 1, 2025, subject to continued service through each vesting date.
[F4]The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on March 2, 2026, subject to continued service through each vesting date.
[F5]The RSUs shall vest as to 1/4 of the total award annually, with the first tranche vesting on March 1, 2027, subject to continued service through each vesting date.
[F6]1/48 of the total option award shall vest monthly, subject to the reporting person's continued service through each vesting date, with the first tranche vesting on April 1, 2026.

Signature

/s/ David Pauling as attorney-in-fact|2026-03-03

Documents

1 file